Sickle Cell Disease MedDRA version: 20.0 Level: LLT Classification code 10040644 Term: Sickle cell disease System Organ Class: 100000004850
Conditions
Interventions
Product Name: GBT440 300 mg capsule
Product Code: GBT440
Pharmaceutical Form: Capsule
Current Sponsor code: GBT440
Concentration unit: m
Sponsors
Global Blood Therapeutics, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All participants must meet the following inclusion criteria: 1. Male or female study participants with Sickle Cell Disease: • Documentation of SCD genotype (HbSS, HbSC, HbSß thalassemia or other sickle cell syndrome variants) may be based on history of laboratory testing or must be confirmed by laboratory testing during screening 2. Participants have had at least 1 episode of VOC in the past 12 months. For study eligibility, VOC is defined as a previously documented episode of ACS or acute painful crisis (for which there was no explanation other than VOC) which required prescription or healthcare professional-instructed use of analgesics for moderate to severe pain (documentation must exist in the patient medical record prior to Screening) 3. Age 12 to 65 years 4. Hemoglobin (Hb) =5.5 and =10.5 g/dL during screening 5. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 90 days prior to signing the ICF and with no anticipated need for dose adjustments or initiation during the study, in the opinion of the Investigator 6. Participants must demonstrate 75% compliance with ePRO measure completion to be randomised (participants will be given an ePRO device for at least 28 days during Screening; participants who have =65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: Any participant who meets one or more of the following criteria will be excluded from participation: 1. More than 10 VOCs within the past 12 months that required a hospital, or emergency room or clinic visit 2. Female who is breast feeding or pregnant 3. Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 60 days of signing the ICF or at any time during the screening period. 4. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior to signing the ICF (i.e., a vaso-occlusive event cannot be within 14 days prior to ICF) 5. Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × ULN 6. Participants with clinically significant bacterial, fungal, parasitic or viral infection which require therapy: • Participants with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed. • Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive 7. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the central laboratory) <30mL/min/1.732 or on chronic dialysis 8. History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy) 9. History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following: • Unstable angina pectoris or myocardial infarction or elective coronary intervention • Congestive heart failure requiring hospitalization • Uncontrolled clinically significant arrhythmias 10. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable) 11. Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device) 12. Inadequate venous access as determined by the Investigator/site staff 13. Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent 14. Receipt of erythropoietin or other hematopoietic growth factors within 28 days of signing ICF or anticipated need for such agents during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: Day 1, Weeks 2,4,6,8,12,16,20,24,36,48,60,72, EOS(+4weeks);Main Objective: The primary objective is to assess the efficacy of GBT440 in adolescents and adults with Sickle Cell Disease (SCD) as measured by improvement in anemia.;Secondary Objective: The secondary objectives are to evaluate the effects of GBT440 compared to placebo on SCD symptom exacerbation and TSS from PRO measurement, measures of anemia and hemolysis, and other clinical measures (e.g., VOC, ACS, hospitalization, RBC transfusions, opioid use).;Primary end point(s): Increase in Hb >1 g/dL from Baseline to Week 24. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Proportion of days with SCD symptom exacerbation during the first 24 weeks of treatment. This is the first-rank secondary endpoint. • Change from Baseline to Weeks 21–24 in the SCDSM TSS • Normalization of reticulocyte count at Week 12/24 (% reticulocytes <1.5 × ULN weeks) • VOC during the treatment period is defined as: A composite of acute painful crisis or ACS and includes the following: ? Moderate to severe pain lasting at least 2 hours ? No explanation other than VOC ? Requires oral or parenteral opioids, ketorolac, or other analgesics prescribed or directed by a healthcare professional ? Must be documented in patient medical record that the patient was seen, or contacted the physician, within 1 day of the event. The event may take place in a medical setting (hospital, clinic, emergency room) ? May include episodes of ACS (ACS is defined as an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X ray • Rate of hospitalization for VOC during the treatment period • Change from Baseline to 24 weeks in hemolysis and related measures: % reticulocytes, unconjugated bilirubin, Hb, dense RBCs • Time to first ACS during the treatment period • Time to first RBC transfusions during the treatment period • Rate of opioid use, calculated as the proportion days that opioids were used each 4-week period as recorded in an eDiary • Length of hospitalization for VOC ;Timepoint(s) of evaluation of this end point: Day 1, Weeks 2,4,6,8,12,16,20,24,36,48,60,72, EOS(+4weeks) | — |
Countries
Canada, Egypt, France, Germany, Ghana, Italy, Jamaica, Kenya, Lebanon, Netherlands, Nigeria, Oman, Turkey, United Kingdom, United States
Contacts
Public ContactSr. Clinical Trial Manager
Global Blood Therapeutics, Inc.
Outcome results
None listed